ketamine has been researched along with Facial Pain in 10 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Facial Pain: Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The analgesic effect of the N-methyl-D-aspartate (NMDA) receptor blocker ketamine in 17 patients (13 females and four males, age 32-88 years) who had suffered neuropathic orofacial pain for time periods ranging from 6 months to 28 years was examined." | 9.09 | Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. ( Rabben, T; Øye, I, 2001) |
| "We examined the analgesic effect of racemic ketamine and its 2 enantiomers in 16 female patients (age: 20-29 years) suffering acute pain after oral surgery and in 7 female patients (age: 42-79 years) suffering chronic neuropathic orofacial pain." | 7.69 | Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. ( Mathisen, LC; Skjelbred, P; Skoglund, LA; Øye, I, 1995) |
| "Ketamine has garnered increased interest for its promising applications in chronic pain treatment, particularly in cases where conventional therapies have proven insufficient." | 5.91 | Ketamine for atypical facial pain and hormonal dysregulation: a case report. ( Darwish, Y; Mahesh, K; Van, S; Willeford, S, 2023) |
| "The analgesic effect of the N-methyl-D-aspartate (NMDA) receptor blocker ketamine in 17 patients (13 females and four males, age 32-88 years) who had suffered neuropathic orofacial pain for time periods ranging from 6 months to 28 years was examined." | 5.09 | Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. ( Rabben, T; Øye, I, 2001) |
| "The clinical efficacy of the noncompetitive N-methyl-d-aspartate receptor antagonist ketamine for treating orofacial pain has already been reported." | 3.72 | Synergistic antinociceptive effects of ketamine and morphine in the orofacial capsaicin test in the rat. ( Alvarez, P; Hernández, A; Paeile, C; Pelissier, T; Saavedra, G, 2003) |
| "We examined the analgesic effect of racemic ketamine and its 2 enantiomers in 16 female patients (age: 20-29 years) suffering acute pain after oral surgery and in 7 female patients (age: 42-79 years) suffering chronic neuropathic orofacial pain." | 3.69 | Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. ( Mathisen, LC; Skjelbred, P; Skoglund, LA; Øye, I, 1995) |
| "ketamine bolus, were treated with 0." | 2.76 | A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: effect of a 1:1 ratio. ( Benítez-Rosario, MA; Feria, M; González-Guillermo, T; Salinas-Martín, A, 2011) |
| "Ketamine has garnered increased interest for its promising applications in chronic pain treatment, particularly in cases where conventional therapies have proven insufficient." | 1.91 | Ketamine for atypical facial pain and hormonal dysregulation: a case report. ( Darwish, Y; Mahesh, K; Van, S; Willeford, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Darwish, Y | 1 |
| Willeford, S | 1 |
| Mahesh, K | 1 |
| Van, S | 1 |
| Matsuura, N | 1 |
| Shibukawa, Y | 1 |
| Kato, M | 1 |
| Ichinohe, T | 1 |
| Suzuki, T | 1 |
| Kaneko, Y | 1 |
| Carter, MJ | 1 |
| Gibbins, J | 1 |
| Senior-Smith, G | 1 |
| Thomas, S | 1 |
| Guest, P | 1 |
| Forbes, K | 1 |
| Burgos, E | 1 |
| Pascual, D | 1 |
| Martín, MI | 1 |
| Goicoechea, C | 1 |
| Alstergren, P | 1 |
| Ernberg, M | 1 |
| Nilsson, M | 1 |
| Hajati, AK | 1 |
| Sessle, BJ | 1 |
| Kopp, S | 1 |
| Sakamoto, E | 1 |
| Shiiba, S | 1 |
| Noma, N | 1 |
| Okada-Ogawa, A | 1 |
| Shinozaki, T | 1 |
| Kobayashi, A | 1 |
| Kamo, H | 1 |
| Koike, K | 1 |
| Imamura, Y | 1 |
| Benítez-Rosario, MA | 1 |
| Salinas-Martín, A | 1 |
| González-Guillermo, T | 1 |
| Feria, M | 1 |
| Alvarez, P | 1 |
| Saavedra, G | 1 |
| Hernández, A | 1 |
| Paeile, C | 1 |
| Pelissier, T | 1 |
| Mathisen, LC | 1 |
| Skjelbred, P | 1 |
| Skoglund, LA | 1 |
| Øye, I | 2 |
| Rabben, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Naloxone Block of Low-dose (Analgetic Dose) Ketamine[NCT00921765] | Phase 4 | 3 participants (Actual) | Interventional | 2009-12-31 | Terminated (stopped due to Problems with patient recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for ketamine and Facial Pain
| Article | Year |
|---|---|
Glutamate-induced temporomandibular joint pain in healthy individuals is partially mediated by peripheral NMDA receptors.
Topics: Adult; Area Under Curve; Double-Blind Method; Estradiol; Excitatory Amino Acid Antagonists; Excitato | 2010 |
A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: effect of a 1:1 ratio.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Dose-Response Relationship, Drug; | 2011 |
Interindividual differences in the analgesic response to ketamine in chronic orofacial pain.
Topics: Adjuvants, Anesthesia; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics | 2001 |
7 other studies available for ketamine and Facial Pain
| Article | Year |
|---|---|
Ketamine for atypical facial pain and hormonal dysregulation: a case report.
Topics: Analgesics; Facial Pain; Humans; Hydrocortisone; Ketamine; Receptors, N-Methyl-D-Aspartate | 2023 |
Ketamine, not fentanyl, suppresses pain-related magnetic fields associated with trigeminally innervated area following CO2 laser stimulation.
Topics: Adult; Analgesics; Facial Pain; Fentanyl; Humans; Ketamine; Lasers, Gas; Magnetoencephalography; Mal | 2008 |
Ketamine: does it have a role in palliative sedation?
Topics: Analgesics; Facial Pain; Humans; Ketamine; Male; Palliative Care; Tongue Neoplasms; Treatment Outcom | 2008 |
Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.
Topics: Analgesics; Analgesics, Opioid; Anesthetics, Dissociative; Animals; Anti-Inflammatory Agents, Non-St | 2010 |
A possible case of complex regional pain syndrome in the orofacial region.
Topics: Aged; Anesthetics, Dissociative; Causalgia; Facial Pain; GABA Modulators; Humans; Injections, Intrav | 2010 |
Synergistic antinociceptive effects of ketamine and morphine in the orofacial capsaicin test in the rat.
Topics: Analgesics; Animals; Capsaicin; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Comb | 2003 |
Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Facial Pain; Female; Follow-Up Studies; Humans; Inciden | 1995 |